Back to News
Market Impact: 0.2
Zacks Initiates Coverage of SSi With Neutral Recommendation
Source: zacks.com
Analyst InsightsHealthcare & BiotechCompany FundamentalsRegulation & Legislation
Zacks initiated coverage of SSII with a Neutral rating, becoming the first Wall Street firm to cover the stock. Expanding robotic-surgery adoption, rising revenue and international growth are offset by persistent losses and regulatory hurdles.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
More News
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- Elon Musk intensifies attack on Ambani over Starlink India launch delay
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- SpaceX’s Wireless Threat Rises With Spectrum Deal
- ‘Piece by piece’: Trump administration vows to dismantle the International Criminal Court with sweeping new sanctions
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs
- AI Tools for CFA Charterholders: An Evidence Standard